Should I prescribe the EzPAP (positive expiratory pressure) device for all patients in my chronic tracheostomy and ventilator unit, given that most have hypoxic brain injury or stroke and only a few have neuromuscular respiratory failure or COPD, and can I bill Medicare for its use as a wellness program?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Do Not Prescribe EzPAP as a Universal "Wellness Program" for Your Chronic Trach/Vent Population

You should not implement blanket EzPAP therapy across your chronic tracheostomy and ventilator unit, and you cannot bill Medicare for this device as a preventive "wellness program" in this population. The evidence does not support universal application of positive expiratory pressure devices in chronically ventilated patients with hypoxic brain injury or stroke, and Medicare does not cover respiratory devices for wellness or prevention—only for specific medical indications with documented therapeutic need.

Why This Approach Is Problematic

Wrong Population for the Evidence Base

The recent studies showing EzPAP efficacy are in acute COPD exacerbations 1, 2, not chronic ventilator-dependent patients with neurological injury. The 2025 RCT by comparing EzPAP to NIV demonstrated improved pH correction and reduced hospital admissions specifically in mild-to-moderate hypercapnic COPD exacerbations 1. Your facility has "just a couple with COPD" and mostly patients with hypoxic brain damage or stroke—this is a fundamentally different population.

The physiological study in healthy adults 3 showed EzPAP increases tidal volume and generates positive pressures, but this was tested in people with normal respiratory mechanics and intact neurological function, not brain-injured patients on chronic mechanical ventilation.

Tracheostomy Changes the Equation

For patients with tracheostomies, the evidence actually supports individualized PEEP application for specific purposes like improving speech 4, not blanket therapy. That study showed patient-controlled PEEP at median 10 cmH₂O improved phonation in neuromuscular patients, but this was:

  • Titrated individually to each patient's needs
  • Under patient control for comfort
  • For a specific therapeutic goal (communication)
  • In neuromuscular disease, not hypoxic brain injury

Brain-Injured Patients Require Different Considerations

The 2025 narrative review on brain-protective ventilation 5 emphasizes that ventilator management in acute brain injury (including stroke and hypoxic-ischemic encephalopathy) must be individualized to preserve intracranial pressure and cerebral perfusion pressure. While moderate PEEP can be used safely with concurrent cerebral monitoring 6, 7, this requires:

  • Active monitoring of ICP and CPP
  • Titration based on individual cerebral physiology
  • Integration with multimodal neuromonitoring

A blanket "wellness program" approach contradicts these principles entirely.

What the Guidelines Actually Say

The 2025 Portuguese guidelines 8 specify home mechanical ventilation indications for:

  • COPD: Persistent PaCO₂ ≥52 mmHg in stable disease
  • Neuromuscular disease: As adjunct to airway clearance therapy
  • Bronchiectasis/CF: Stable persistent hypercapnia or bridge to transplant

The 2015 British Thoracic Society guidelines 9 explicitly state that patients with neuromuscular weakness or established ventilatory failure should receive NIV support, not isolated positive pressure therapy.

None of these guidelines support prophylactic positive pressure devices for chronic ventilator patients without specific indications.

The Medicare Billing Problem

Medicare does not cover respiratory devices for:

  • "Wellness programs"
  • Prevention in the absence of documented disease
  • Blanket application without individual medical necessity

To bill for any respiratory device, you need:

  • Specific diagnosis codes indicating medical necessity
  • Documentation of therapeutic goals
  • Evidence of patient-specific need
  • Demonstration that the device addresses an active medical problem

Attempting to bill Medicare for EzPAP as preventive therapy in patients already on chronic mechanical ventilation would likely be considered inappropriate billing.

The Appropriate Clinical Approach

Consider EzPAP or similar devices only for specific indications:

  1. COPD patients with acute hypercapnic exacerbations (you have "just a couple")

    • Document baseline and post-treatment blood gases
    • Use as alternative when NIV unavailable
    • Based on 1, 2
  2. Neuromuscular patients needing airway clearance augmentation (you have 3-4)

    • As adjunct to cough assist and therapy vest
    • When secretion management is inadequate with current therapy
    • Based on 8
  3. Individual patients with documented need for improved speech (trach patients)

    • Titrate PEEP individually
    • Allow patient control
    • Based on 4

Do not use for:

  • Chronic hypoxic brain injury patients on stable ventilation
  • Stroke patients without specific respiratory indication
  • "Wellness" or prevention in already-ventilated patients

How to Respond to Administration

Your response should clarify:

  1. The facilities without trachs/vents have different patient populations where preventive respiratory therapy might be appropriate (e.g., post-surgical patients at risk for atelectasis, ambulatory COPD patients)

  2. Your patients are already on maximal ventilatory support—adding another device without specific indication doesn't constitute "keeping patients healthy"

  3. Evidence-based medicine requires matching interventions to patient populations—the studies supporting EzPAP are in acute COPD exacerbations, not chronic vent-dependent neurological patients

  4. Medicare compliance requires individual medical necessity—you cannot bill for blanket "wellness" programs with durable medical equipment

  5. You are willing to use EzPAP for appropriate indications when individual patients meet evidence-based criteria

Common Pitfalls to Avoid

  • Don't confuse "doing something" with "doing something beneficial"—adding interventions without evidence can increase patient discomfort, staff burden, and infection risk
  • Don't let corporate protocols override clinical judgment—facilities without physicians may implement programs that seem reasonable but lack medical appropriateness for specific populations
  • Don't assume devices safe in one population are universally applicable—brain-injured patients have unique vulnerabilities regarding ICP and cerebral perfusion
  • Don't bill Medicare for services that don't meet medical necessity criteria—this creates compliance risk for you and the facility

Your opposition is medically sound and should be maintained. Offer to develop evidence-based protocols for appropriate EzPAP use in the small subset of patients who might benefit, but resist blanket implementation.

References

Research

Effect of the EzPAP system on tidal volume and airway pressures in healthy adults.

Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR, 2026

Research

Brain Protective Ventilation Strategies in Severe Acute Brain Injury.

Current neurology and neuroscience reports, 2025

Related Questions

Does the medical literature support the use of the EzPAP (positive airway pressure) system to improve lung expansion and prevent adverse clinical outcomes or exacerbations of comorbidities?
Is the EzPAP (positive airway pressure) system an effective preventive treatment for all residents in skilled‑nursing or long‑term‑care facilities regardless of diagnosis?
Is it permissible under Medicare regulations to use EzPAP (positive expiratory pressure device), Acapella (oscillating positive expiratory pressure device), Cough Assist (mechanical insufflator‑exsufflator), and Therapy Vest (high‑frequency chest wall oscillation) as a blanket wellness program for skilled nursing facility and long‑term care patients without documented respiratory indications, or does this constitute fraudulent billing?
Is it appropriate to prescribe EzPAP (EzPAP device) for all residents in a skilled‑nursing or long‑term‑care facility as a blanket preventive measure regardless of diagnosis, and can it be billed under Medicare Part A?
In a stable asthmatic patient with an occasional non‑productive cough, is routine use of incentive spirometry, ezPAP (expiratory positive airway pressure), or Acapella (vibratory clearance device) indicated?
In a 50-year-old woman with abdominal bloating and pain whose prior transabdominal and transvaginal ultrasound did not visualize the ovaries, what is the appropriate next diagnostic step?
How can I determine if a female patient is detoxified (i.e., has completed acute withdrawal, is clinically stable with normal vital signs, a CIWA‑Ar score ≤8 for at least 24 hours, has been abstinent for 3–5 days, and opioid‑free for ≥7 days) before starting naltrexone?
Can you provide a comprehensive overview of Parkinson disease, including its epidemiology, etiology, pathophysiology, clinical signs and symptoms, physical examination findings, diagnostic criteria, treatment options, and prognosis?
What is the appropriate dosing regimen of colchicine for an acute gout flare in an adult with normal renal and hepatic function?
What alternative hypertension regimen is recommended for a patient on lisinopril 40 mg and amlodipine who has bilateral lower‑extremity edema?
In a patient taking lisinopril 40 mg and amlodipine, what is the best calcium‑channel blocker to add or substitute, considering a resting heart rate ≤60 bpm or significant conduction disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.